Download PDF
CC BY-NC-ND 4.0 · Indian Journal of Neurotrauma 2020; 17(02): 095-103
DOI: 10.1055/s-0040-1713348
Original Article

Management Dilemmas in Patients with Traumatic Brain Injury on Anticoagulants

Srinivas Dwarakanath
1   Department of Neurosurgery, National Institute of Mental Health and Neurosciences, Bengaluru, Karnataka, India
,
Harsh Deora
1   Department of Neurosurgery, National Institute of Mental Health and Neurosciences, Bengaluru, Karnataka, India
› Author Affiliations
› Further Information
   Permissions and Reprints

Abstract

Introduction A normal individual with normal hemostasis maintains a balance between thrombus formation and destruction using a complex interaction between the smooth vascular endothelium, the coagulation cascade, the platelet aggregation system, and the fibrinolysis mechanism. However, in patients who are on either antiplatelet drugs (APDs) or anticoagulants (ACDs), this normal homeostasis is altered. This is further altered with traumatic brain injury (TBI) and thus, we need specific guidelines to address this subpopulation to decide the length of observation, avoid unnecessary hospitalization, and relieve the economic burden. There exists a very few randomized controlled trials (RCTs) for this clinical question and a thorough risk–benefit analysis for each patient is prudent before making clinical decisions.

Materials and Methods This is a review article based on available evidence published in literature.

Results There are multiple therapeutic drugs which act on various stages of the coagulation mechanism. These include antiplatelet agents, Vitamin K antagonists, Heparin, Antithrombin III, and Glycoprotein IIb/IIIA inhibitors. While the initial management of head injuries depends on the severity of head injuries, management of head injuries in patients on anticoagulants needs to be approached with care and caution. There are multiple dilemmas including role of CT scans, duration and reason for admission, when to restart anticoagulation, etc. We suggest the recommendations based on available literature; however, no evidence can be given as these are not based on any RCTs, due to paucity of such studies.

Conclusion The guidelines are based on previously conducted trials and consensus. We have attempted to provide a pragmatic and practical approach to such cases with the hope that it will ensure minimum risks with the best possible patient outcomes. The entire journey from patient presentation to follow-up has been covered in this article and we hope this would be useful to all practicing in the field of neurotrauma.

Keywords

traumatic brain injury - contusion - anticoagulants - antiplatelets


Publication History

Article published online:
02 September 2020

© .

Thieme Medical and Scientific Publishers Private Ltd.
A-12, Second Floor, Sector -2, NOIDA -201301, India

 

  • References

  • 1 Channabasavanna SM, Gururaj G, Das BS, Kaliaperumal VG. Epidemiology of Head Injuries in Bangalore. National Institute of Mental Health and Neuro Sciences. Bengaluru, Karnataka: Karnataka State Council for Science and Technology; 1993
    Google Scholar
  • 2 Harter K, Levine M, Henderson SO. Anticoagulation drug therapy: a review. West J Emerg Med 2015; 16 (01) 11-17
    CrossrefPubMedGoogle Scholar
  • 3 Madhugiri VS, Singh V, Kishore K, Reddy A, Bysani P. Peri-operative management of patients on anti-platelet agents and anticoagulants and prophylaxis for venous thromboembolism in the neurosurgical setting-summary of evidence and practice guidelines. Current Pract Neurosci 2019; 3: 1-13
    PubMedGoogle Scholar
  • 4 Deora H, Perez RM, Agrawal A, Salazar LRM. Commentary to: External Ventricular Drainage before endovascular treatment in patients with aneurysmal subarachnoid hemorrhage in acute period: its relation to hemorrhagic complications. Neurointervention 2019; 14: 1-3
    CrossrefPubMedGoogle Scholar
  • 5 Pieracci FM, Eachempati SR, Shou J, Hydo LJ, Barie PS. Degree of anticoagulation, but not warfarin use itself, predicts adverse outcomes after traumatic brain injury in elderly trauma patients. J Trauma 2007; 63 (03) 525-530
    CrossrefPubMedGoogle Scholar
  • 6 Mason S, Kuczawski M, Teare MD. et al. AHEAD Study: an observational study of the management of anticoagulated patients who suffer head injury. BMJ Open 2017; 7 (01) e014324
    CrossrefPubMedGoogle Scholar
  • 7 Woo CH, Patel N, Conell C. et al. Rapid Warfarin reversal in the setting of intracranial hemorrhage: a comparison of plasma, recombinant activated factor VII, and prothrombin complex concentrate. World Neurosurg 2014; 81 (01) 110-115
    CrossrefPubMedGoogle Scholar
  • 8 Pinner NA, Hurdle AC, Oliphant C, Reaves A, Lobo B, Sills A. Treatment of warfarin-related intracranial hemorrhage: a comparison of prothrombin complex concentrate and recombinant activated factor VII. World Neurosurg 2010; 74 (06) 631-635
    CrossrefPubMedGoogle Scholar
  • 9 Shakur H, Roberts I, Bautista R. et al. CRASH-2 trial collaborators. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial. Lancet 2010; 376 (9734) 23-32
    CrossrefPubMedGoogle Scholar
  • 10 CRASH-2 Collaborators, Intracranial Bleeding Study. Effect of tranexamic acid in traumatic brain injury: a nested randomised, placebo controlled trial (CRASH-2 Intracranial Bleeding Study). BMJ 2011; 343: d3795
    CrossrefPubMedGoogle Scholar
  • 11 Downey DM, Monson B, Butler KL. et al. Does platelet administration affect mortality in elderly head-injured patients taking antiplatelet medications?. Am Surg 2009; 75 (11) 1100-1103
    CrossrefPubMedGoogle Scholar
  • 12 Ducruet AF, Hickman ZL, Zacharia BE. et al. Impact of platelet transfusion on hematoma expansion in patients receiving antiplatelet agents before intracerebral hemorrhage. Neurol Res 2010; 32 (07) 706-710
    CrossrefPubMedGoogle Scholar
  • 13 Briggs A, Gates JD, Kaufman RM, Calahan C, Gormley WB, Havens JM. Platelet dysfunction and platelet transfusion in traumatic brain injury. J Surg Res 2015; 193 (02) 802-806
    CrossrefPubMedGoogle Scholar
  • 14 Kapapa T, Röhrer S, Struve S. et al. Desmopressin acetate in intracranial haemorrhage. Neurol Res Int 2014; 2014: 298767
    CrossrefPubMedGoogle Scholar
  • 15 Naidech AM, Maas MB, Levasseur-Franklin KE. et al. Desmopressin improves platelet activity in acute intracerebral hemorrhage. Stroke 2014; 45 (08) 2451-2453
    CrossrefPubMedGoogle Scholar
  • 16 Yutthakasemsunt S, Kittiwatanagul W, Piyavechvirat P, Thinkamrop B, Phuenpathom N, Lumbiganon P. Tranexamic acid for patients with traumatic brain injury: a randomized, double-blinded, placebo-controlled trial. BMC Emerg Med 2013; 13: 20
    CrossrefPubMedGoogle Scholar
  • 17 Chakroun-Walha O, Samet A, Jerbi M. et al. Benefits of the tranexamic acid in head trauma with no extracranial bleeding: a prospective follow-up of 180 patients. Eur J Trauma Emerg Surg 2019; 45 (04) 719-726
    CrossrefPubMedGoogle Scholar
  • 18 The CRASH-3 Collaborators. Effects of tranexamic acid (TA) on death, disability, vascular occlusive events and other morbidities in patients with acute traumatic brain injury: a randomised placebo-controlled trial. Lancet 394 (10210) 1713-1723
    PubMedGoogle Scholar
  • 19 Carney N, Totten AM, O’Reilly C. et al. Guidelines for the management of severe traumatic brain injury, fourth edition. Neurosurg 2017; 80: 6-15
    CrossrefPubMedGoogle Scholar
  • 20 Hawryluk GW, Furlan JC, Austin JW, Fehlings MG. Survey of neurosurgical management of central nervous system hemorrhage in patients receiving anticoagulation therapy: current practice is highly variable and may be suboptimal. World Neurosurg 2011; 76 (3-4) 299-303
    CrossrefPubMedGoogle Scholar
  • 21 Wiegele M, Schöchl H, Haushofer A. et al. Diagnostic and therapeutic approach in adult patients with traumatic brain injury receiving oral anticoagulant therapy: an Austrian interdisciplinary consensus statement. Crit Care 2019; 23 (01) 62
    CrossrefPubMedGoogle Scholar